Skip to main content
SpringerLink
Log in

Pulmonary Hypertension in Older Patients

  • Chapter
  • First Online:
Aging and Lung Disease

Part of the book series: Respiratory Medicine ((RM))

  • 1174 Accesses

Abstract

Shortness of breath is a common complaint in older patients, and it can be quite difficult to determine the etiology. Multiple diseases that can present with dyspnea including anemia, pulmonary and cardiac disease disproportionately affect the aging population. There is increasing recognition that pulmonary hypertension (PH) is an important cause of dyspnea in the elderly. PH can lead to insidious and progressive dyspnea and hypoxemia and can be easily missed without a reasonable index of suspicion. The presence of PH has prognostic implications and, in some instances, provides a therapeutic target. Thus, it is important to consider PH in the evaluation of dyspnea in the older patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mahler DA, Fierro-Carrion G, Baird JC. Evaluation of dyspnea in the elderly. Clin Geriatr Med. 2003;19(1):19–33. v.

    Article  PubMed  Google Scholar 

  2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):S43–54.

    Article  PubMed  Google Scholar 

  3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352(9129):719–25.

    Article  PubMed  CAS  Google Scholar 

  4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30.

    Article  PubMed  Google Scholar 

  5. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011;139:128–37.

    Google Scholar 

  6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16): 1655–65.

    Article  PubMed  CAS  Google Scholar 

  7. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30(6):1103–10.

    Article  PubMed  CAS  Google Scholar 

  8. Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV Med. 2010;11(10):620–34.

    Article  PubMed  CAS  Google Scholar 

  9. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68–74.

    Article  PubMed  CAS  Google Scholar 

  10. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088–93.

    Article  PubMed  CAS  Google Scholar 

  11. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792–800.

    Article  PubMed  Google Scholar 

  12. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.

    Article  PubMed  Google Scholar 

  13. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123(2):344–50.

    Article  PubMed  Google Scholar 

  14. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006;92(7):926–32.

    Article  PubMed  CAS  Google Scholar 

  15. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2): 151–7.

    Article  PubMed  Google Scholar 

  16. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043–50.

    Article  PubMed  Google Scholar 

  17. Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752–9.

    Article  PubMed  Google Scholar 

  18. Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol. 2007;34(12):2431–7.

    PubMed  Google Scholar 

  19. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger Jr TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986;29(4): 515–24.

    Article  PubMed  CAS  Google Scholar 

  20. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252–60.

    Article  PubMed  Google Scholar 

  21. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8.

    Article  PubMed  Google Scholar 

  22. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. Ann Hepatol. 2008;7(4):321–30.

    PubMed  Google Scholar 

  23. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562–76.

    Article  PubMed  Google Scholar 

  24. Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.

    Article  PubMed  Google Scholar 

  25. Redfield MM. Understanding “diastolic” heart failure. N Engl J Med. 2004;350(19): 1930–1.

    Article  PubMed  CAS  Google Scholar 

  26. Zhang Y, Safar ME, Iaria P, Agnoletti D, Protogerou AD, Blacher J. Prevalence and prognosis of left ventricular diastolic dysfunction in the elderly: The PROTEGER Study. Am Heart J. 2010;160(3):471–8.

    Article  PubMed  Google Scholar 

  27. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1): S85–96.

    Article  PubMed  Google Scholar 

  28. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37(1):183–8.

    Article  PubMed  CAS  Google Scholar 

  29. Grigioni F, Potena L, Galie N, et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006;25(10):1241–6.

    Article  PubMed  Google Scholar 

  30. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106(2):284–6.

    Article  PubMed  Google Scholar 

  31. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7(6):1011–6.

    Article  PubMed  Google Scholar 

  32. Butler J, Stankewicz MA, Wu J, et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant. 2005; 24(2):170–7.

    Article  PubMed  Google Scholar 

  33. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189–94.

    Article  PubMed  Google Scholar 

  34. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127(5):1531–6.

    Article  PubMed  Google Scholar 

  35. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002;166(3):314–22.

    Article  PubMed  Google Scholar 

  36. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl):39S–51.

    Article  PubMed  Google Scholar 

  37. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 2009;30(4):458–70.

    Article  PubMed  Google Scholar 

  38. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010;182(3):325–31.

    Article  PubMed  Google Scholar 

  39. Hoeper MM. Treating pulmonary hypertension in COPD: where do we start? Eur Respir J. 2008;32(3):541–2.

    Article  PubMed  CAS  Google Scholar 

  40. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular ­dysfunction in patients with severe pulmonary disease. Chest. 1998;113(3):576–83.

    Article  PubMed  CAS  Google Scholar 

  41. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393–9.

    Article  PubMed  Google Scholar 

  42. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008;76(3):288–94.

    Article  PubMed  CAS  Google Scholar 

  43. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3): 746–52.

    Article  PubMed  Google Scholar 

  44. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715–21.

    Article  PubMed  CAS  Google Scholar 

  45. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131(3):650–6.

    Article  PubMed  Google Scholar 

  46. Nadrous HF, Pellikka PA, Krowka MJ, et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(6 Suppl):616S–7.

    Article  PubMed  Google Scholar 

  47. Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J. 1996;9(4): 787–94.

    Article  PubMed  CAS  Google Scholar 

  48. Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009;104(9):1300–6.

    Article  PubMed  Google Scholar 

  49. Sajkov D, Cowie RJ, Thornton AT, Espinoza HA, McEvoy RD. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 1994;149(2 Pt 1): 416–22.

    PubMed  CAS  Google Scholar 

  50. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax. 2000;55(11):934–9.

    Article  PubMed  CAS  Google Scholar 

  51. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345(20):1465–72.

    Article  PubMed  CAS  Google Scholar 

  52. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130(1):172–5.

    Article  PubMed  Google Scholar 

  53. Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore). 2006;85(5):253–62.

    Article  Google Scholar 

  54. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–64.

    Article  PubMed  CAS  Google Scholar 

  55. Dentali F, Donadini M, Gianni M, et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res. 2009;124(3):256–8.

    Article  PubMed  CAS  Google Scholar 

  56. Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3(7):568–70.

    Article  PubMed  Google Scholar 

  57. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):S3–9.

    Article  PubMed  CAS  Google Scholar 

  58. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325–31.

    Article  PubMed  CAS  Google Scholar 

  59. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3(7):564–7.

    Article  PubMed  Google Scholar 

  60. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103(3):685–92.

    Article  PubMed  CAS  Google Scholar 

  61. Brecker SJ, Gibbs JS, Fox KM, Yacoub MH, Gibson DG. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J. 1994;72(4):384–9.

    Article  PubMed  CAS  Google Scholar 

  62. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–21.

    Article  PubMed  Google Scholar 

  63. Bernadac P, Cuny G, Vaillant G, Didier F, Stines J, Plenat F. Radiologic study of the pulmonary arterial circulation in the aged. J Radiol Electrol Med Nucl. 1975;56 suppl 1:177–9.

    PubMed  Google Scholar 

  64. Mackay EH, Banks J, Sykes B, Lee G. Structural basis for the changing physical properties of human pulmonary vessels with age. Thorax. 1978;33(3):335–44.

    Article  PubMed  CAS  Google Scholar 

  65. Hosoda Y, Kawano K, Yamasawa F, Ishii T, Shibata T, Inayama S. Age-dependent changes of collagen and elastin content in human aorta and pulmonary artery. Angiology. 1984;35(10): 615–21.

    Article  PubMed  CAS  Google Scholar 

  66. Ongkana N, Tohno S, Payo IM, Azuma C, Moriwake Y, Minami T, et al. Age-related changes of elements in thoracic and abdominal aortas and coronary, common carotid, pulmonary, splenic, common iliac, and uterine arteries and relationships in elements among their arteries. Biol Trace Elem Res. 2006;117(1–3):23–38.

    Google Scholar 

  67. Matsuoka S, Uchiyama K, Shima H, Ueno N, Oish S, Nojiri Y. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol. 2003;180(2):513–8.

    PubMed  Google Scholar 

  68. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888–94.

    Article  PubMed  CAS  Google Scholar 

  69. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663–70.

    Article  PubMed  Google Scholar 

  70. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118(21):2183–9.

    Article  PubMed  Google Scholar 

  71. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol. 2006;97(1):123–6.

    Article  PubMed  Google Scholar 

  72. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005;127(5): 1637–46.

    Article  PubMed  Google Scholar 

  73. Sirithanakul K, Mubarak KK. Pulmonary arterial hypertension: new treatments are improving outcomes. J Fam Pract. 2004;53(12):959–69.

    PubMed  Google Scholar 

  74. van Belle A, Buller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295(2):172–9.

    Article  PubMed  Google Scholar 

  75. Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology. 2007;242(1):15–21.

    Article  PubMed  Google Scholar 

  76. Bergin CJ, Rios G, King MA, Belezzuoli E, Luna J, Auger WR. Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR Am J Roentgenol. 1996;166(6):1371–7.

    PubMed  CAS  Google Scholar 

  77. Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680–4.

    Article  PubMed  Google Scholar 

  78. Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001;120(3):894–9.

    Article  PubMed  CAS  Google Scholar 

  79. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8): 865–70.

    Article  PubMed  CAS  Google Scholar 

  80. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004;43(5):764–70.

    Article  PubMed  CAS  Google Scholar 

  81. Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005; 25(3):509–13.

    Article  PubMed  CAS  Google Scholar 

  82. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173(7):744–50.

    Article  PubMed  CAS  Google Scholar 

  83. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170(4): 360–5.

    Article  PubMed  Google Scholar 

  84. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29(4):737–44.

    Article  PubMed  CAS  Google Scholar 

  85. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.

    Article  PubMed  CAS  Google Scholar 

  86. Willens HJ, Fertel DP, Qin J, Labrador E, Lowery MH. Effects of age and pulmonary arterial hypertension on the different phases of right atrial function. Int J Cardiovasc Imaging. 2008;24(7):703–10.

    Article  PubMed  Google Scholar 

  87. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80(5):1207–21.

    Article  PubMed  CAS  Google Scholar 

  88. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900.

    Article  PubMed  CAS  Google Scholar 

  89. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4): 580–7.

    Article  PubMed  CAS  Google Scholar 

  90. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76–81.

    Article  PubMed  CAS  Google Scholar 

  91. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214–21.

    Article  PubMed  CAS  Google Scholar 

  92. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43(7):1149–53.

    Article  PubMed  CAS  Google Scholar 

  93. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

    Article  PubMed  CAS  Google Scholar 

  94. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    Article  PubMed  CAS  Google Scholar 

  95. Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart. 2009;95(18):1531–6.

    Article  PubMed  CAS  Google Scholar 

  96. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–9.

    Article  PubMed  CAS  Google Scholar 

  97. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102(19):2434–40.

    Article  PubMed  CAS  Google Scholar 

  98. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.

    Article  PubMed  CAS  Google Scholar 

  99. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025–30.

    Article  PubMed  CAS  Google Scholar 

  100. Tilton RG, Munsch CL, Sherwood SJ, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther. 2000;13(2):87–97.

    Article  PubMed  CAS  Google Scholar 

  101. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441–7.

    Article  PubMed  Google Scholar 

  102. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263(5579):663–5.

    Article  PubMed  CAS  Google Scholar 

  103. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66(2): 334–8.

    Article  PubMed  CAS  Google Scholar 

  104. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–8.

    Article  PubMed  CAS  Google Scholar 

  105. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007;132(3):757–63.

    Article  PubMed  CAS  Google Scholar 

  106. Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet. 2008;47(9):611–8.

    Article  PubMed  CAS  Google Scholar 

  107. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586–9.

    Article  PubMed  Google Scholar 

  108. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8):1672–81.

    Article  PubMed  CAS  Google Scholar 

  109. Voswinckel R, Ghofrani HA, Grimminger F, Seeger W, Olschewski H. Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. Ann Intern Med. 2006;144(2):149–50.

    PubMed  Google Scholar 

  110. Ewert R, Glaser S, Opitz C. Iloprost in pulmonary hypertension. Expert Rev Respir Med. 2008;2(6):689–702.

    Article  PubMed  CAS  Google Scholar 

  111. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26(18):1895–902.

    Article  PubMed  CAS  Google Scholar 

  112. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–9.

    Article  PubMed  CAS  Google Scholar 

  113. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30(6):1096–102.

    Article  PubMed  CAS  Google Scholar 

  114. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25): 1866–70.

    Article  PubMed  CAS  Google Scholar 

  115. Chapman TH, Wilde M, Sheth A, Madden BP. Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use? Vascul Pharmacol. 2009;51(2–3):90–5.

    Article  PubMed  CAS  Google Scholar 

  116. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131(3):897–9.

    Article  PubMed  Google Scholar 

  117. Gunther A, Enke B, Markart P, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J. 2007;29(4):713–9.

    Article  PubMed  CAS  Google Scholar 

  118. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis. Pneumologie. 2000;54(3):133–42.

    Article  PubMed  CAS  Google Scholar 

  119. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001;120(3):866–72.

    Article  PubMed  CAS  Google Scholar 

  120. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681–6.

    Google Scholar 

  121. Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The nocturnal oxygen therapy trial – NOTT). Chest. 1980;78(3): 419–20.

    Google Scholar 

  122. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(3):270–8.

    Article  PubMed  CAS  Google Scholar 

  123. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J. 2008;31(4):759–64.

    Article  PubMed  CAS  Google Scholar 

  124. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–28.

    Article  PubMed  CAS  Google Scholar 

  125. Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998;82(6):749–55.

    Article  PubMed  CAS  Google Scholar 

  126. Sueta CA, Gheorghiade M, Adams Jr KF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995;75(3):34A–43.

    Article  PubMed  CAS  Google Scholar 

  127. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54.

    Article  PubMed  CAS  Google Scholar 

  128. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail. 2002;8(3):124–7.

    Article  PubMed  Google Scholar 

  129. Lewis GD, Semigran MJ. The emerging role for type 5 phosphodiesterase inhibition in heart failure. Curr Heart Fail Rep. 2006;3(3):123–8.

    Article  PubMed  CAS  Google Scholar 

  130. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555–62.

    Article  PubMed  CAS  Google Scholar 

  131. Packer M, Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325(21):1468–75.

    Article  PubMed  CAS  Google Scholar 

  132. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006;3(7):594–600.

    Article  PubMed  Google Scholar 

  133. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003;167(8): 1139–41.

    Article  PubMed  Google Scholar 

  134. Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol. 2005;42(2):41–5.

    Article  PubMed  CAS  Google Scholar 

  135. Jais X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Pulmonary, Allergy & Critical Care Division Perelman Center for Advanced Medicine, West Pavilion 3400 Spruce Street, Philadelphia, PA, USA

    Kerri Akaya Smith

  2. Pulmonary Vascular Disease Program, Pulmonary Critical Care Medicine, Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, PBB CA-3, Boston, MA, USA

    Aaron B. Waxman (Director)

Authors
  1. Kerri Akaya Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron B. Waxman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron B. Waxman .

Editor information

Editors and Affiliations

  1. School of Medicine, Pulmonary and Critical Care Medicine, Yale University, Cedar Street 330, New Haven, 06520-8057, Connecticut, USA

    Margaret Pisani

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Smith, K.A., Waxman, A.B. (2012). Pulmonary Hypertension in Older Patients. In: Pisani, M. (eds) Aging and Lung Disease. Respiratory Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-727-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-727-3_6

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-726-6

  • Online ISBN: 978-1-60761-727-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation